• Waters Corporation recently reported a strong first quarter of 2026, with adjusted earnings per share up 20% and revenues rising very large, lifted by the early contribution of the acquired BD Biosciences and Diagnostic Solutions businesses.
• At the same time, Waters advanced its technology and diagnostics portfolio with FDA 510(k) clearance for the BD BACTEC FXI Culture System and the launch of two high-performance mass spectrometry platforms aimed at complex multiomics and imaging workflows.
• We’ll now examine how the BD BACTEC FXI Culture System’s FDA clearance and broader product launches may reshape Waters’ investment narrative.

This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

Waters Investment Narrative Recap

To own Waters, you need to believe it can turn its expanded life sciences and diagnostics footprint into durable growth while executing a complex BD Biosciences and Diagnostic Solutions integration. The BD BACTEC FXI FDA clearance supports the near term catalyst of validating that acquisition, but it does not remove the execution and synergy risk that still sits at the center of the story.

The BD BACTEC FXI Culture System news matters most here because it squarely tests whether Waters can translate BD Diagnostic Solutions’ innovation into regulatory wins and commercial traction. If FXI adoption scales as Waters ramps its new mass spectrometry platforms, the combined portfolio could reinforce recurring revenue growth and help offset pressure in more cyclical academic and pharma discovery budgets.

Yet beneath the excitement around FXI and new omics platforms, investors still need to keep a close eye on...

Waters’ narrative projects $7.5 billion revenue and $1.4 billion earnings by 2029.

Uncover how Waters' forecasts yield a $393.14 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$8.4 billion and earnings near US$1.4 billion by 2029, so if you worry that slower M&A and software investment could leave Waters behind in more integrated digital labs, this latest diagnostics and omics news might either ease those concerns or sharpen them, depending on how you see the story evolving from here.

Explore 3 other fair value estimates on Waters - why the stock might be worth just $393.14!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Waters research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Waters research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Waters' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.